TB-500 Half-Life and Mechanism: What Is Documented

Cover illustration: AI-generated editorial artwork. Conceptual only; not an exact molecular structure, actual laboratory result or evidence of clinical effects.

Searching for TB-500’s half-life returns confident numbers from many websites. Searching the peer-reviewed literature returns no pharmacokinetic study of the heptapeptide at all. This article sets out what is actually documented: metabolite identification from doping control, and a mechanism inferred from work on the parent protein.

For laboratory research use only. The research materials supplied by HealthyWelness are not approved medicines, foods or cosmetics and are not for human or veterinary use. This article summarises published research and is not medical advice.

Key points

No published half-life for N-acetylated LKKTETQ was found.
Metabolites have been characterised in vitro and detected in equine urine and plasma.
Mechanism comes from mapping thymosin beta-4’s activities to short sequences.
Full-length Tβ4 data should not be transferred to a 7-residue fragment.
Methionine oxidation of Tβ4 produces a species with distinct reported activity.

What is documented: the doping-control study

The most substantial analytical work on TB-500 comes from equine sports testing. Researchers identified the key ingredient of a commercial preparation as the heptapeptide LKKTETQ with an acetylated N-terminus, corresponding to residues 17–23 of thymosin beta-4. They first characterised possible metabolites by in vitro incubation, then isolated the parent peptide and its metabolites from equine urine and plasma by solid-phase extraction and analysed them by LC-MS (Ho et al., 2012).

Element	What was established	What it does not establish
Identity of commercial TB-500	Ac-LKKTETQ	Whether all products match
Metabolites	Identified in vitro, then targeted in vivo	Rate of clearance
Detection	Parent and metabolites measurable in urine and plasma	Half-life or exposure

Detection methods are designed to answer “was it administered?”, not “how long does it last?”. That is why a validated detection method can exist without a half-life figure.

Why no half-life has been published

Pharmacokinetic studies are usually run by sponsors preparing a regulatory submission. TB-500 has no such programme. Full-length thymosin beta-4 has progressed to clinical trials in several areas (Goldstein et al., 2015), but those studies used the 43-residue protein. A heptapeptide has different clearance, different protease susceptibility and different distribution, so Tβ4 pharmacokinetics cannot be borrowed.

The mechanism, as far as it is mapped

Thymosin beta-4 is the main intracellular G-actin-sequestering peptide in most vertebrate cells (Hannappel, 2007). It is largely unstructured in solution and folds on binding actin, and reviews have argued that this flexibility lets it engage multiple partners (Yarmola et al., 2007). Sosne and colleagues mapped distinct activities to short sequences within it:

Region	Sequence	Activity attributed
N-terminal tetrapeptide	Ac-SDKP (1-4)	Anti-inflammatory, anti-fibrotic
N-terminal 15-mer	1-15	Cell survival, anti-apoptotic
Central actin-binding domain	LKKTET (17-22) + Q	Angiogenesis, cell migration, wound repair

TB-500 isolates the third of these. That is the mechanistic basis for it, and also its limitation: the Ac-SDKP region and the rest of the molecule are absent, so activities mapped to them should not be expected. See what is TB-500?

An instructive complication: the sulfoxide

Thymosin beta-4 contains a methionine. Its oxidised form, thymosin beta-4 sulfoxide, was found to be generated by monocytes in the presence of glucocorticoids and to inhibit neutrophil chemotaxis in vitro. In a mouse paw-oedema model the oxidised peptide, but not the native form, was a potent inhibitor (Young et al., 1999). Oxidation of a methionine is usually treated as degradation; here it produced a species with its own activity. The heptapeptide LKKTETQ contains no methionine, so this particular chemistry does not apply to TB-500, but it is a useful reminder that a modified peptide is a different molecule, not simply a damaged one.

How to read half-life claims

Ask for the citation. A number without a PMID or DOI has no provenance.
Check which molecule was measured. Tβ4 and TB-500 are routinely conflated.
Check the species. The available analytical work is equine.
Distinguish detection window from half-life. A stable metabolite can be detectable long after the parent peptide has cleared.

Handling implications

Since no pharmacokinetic data guide experimental timing, measurements should be planned from the biology being studied rather than from an assumed exposure curve. In the vial, TB-500 is a short, basic, water-soluble peptide with no methionine or cysteine, which makes it less oxidation-prone than many peptides. Store powder at −20 °C and solutions at 2–8 °C, and see reconstituting TB-500. Our TB-500 research peptide is supplied as a lyophilized powder. Which sequence a supplier means by “TB-500” varies, so the sequence stated on a report is what identifies the material. Certificates are available for listed products — contact us for the latest report. See quality and documentation for what a report can and cannot establish. Concentrations: peptide reconstitution calculator.

Open questions

What is the plasma half-life of Ac-LKKTETQ in any species?
Does the isolated heptapeptide reproduce the actin-related activities of the region within the intact protein?
Do its metabolites retain any activity, as some Semax fragments appear to?

Frequently asked questions

What is the half-life of TB-500?

No peer-reviewed pharmacokinetic study of the acetylated LKKTETQ heptapeptide reports a half-life, as far as we found. Figures circulating online are not traceable to a published measurement.

How does TB-500 work?

It reproduces the central actin-binding region of thymosin beta-4, residues 17-23, which published work links to angiogenesis, cell migration and wound-repair processes. The mechanism is inferred from studies of that region within the full protein.

What is known about its metabolism?

An equine doping-control study identified metabolites of N-acetylated LKKTETQ after in vitro incubation and developed an LC-MS method to detect the parent peptide and its metabolites in urine and plasma.

Does thymosin beta-4 itself have a known half-life?

The full protein has been studied clinically, but its pharmacokinetics should not be transferred to a seven-residue fragment, which is a different molecule with different clearance.

Why does the oxidised form of thymosin beta-4 matter?

Thymosin beta-4 sulfoxide, the methionine-oxidised form, was reported to have anti-inflammatory activity that the native form lacked in a mouse model. Oxidation is not always simply degradation.